Dr Catherine Smith speaks to ecancer at the ASH 2019 meeting in Orlando about a study evaluating emerging mutations in acute myeloid leukaemia (AML) patients who relapsed while receiving gilteritinib therapy in the phase III ADMIRAL trial.
She explains that they looked at 40 patients who had relapsed on gilteritinib therapy and who were then analysed by next-generation sequencing using the Archer Core Myeloid Panel.
Dr Smith reports that in patients who relapsed the most common mutations were Ras/MAPK pathway gene mutations.
ecancer's filming has been kindly supported by AbbVie through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.